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Abstract
Patients with Crohn's disease (CD) frequently require cross-sectional imaging. Magnetic resonance
enterography (MRE) is an accurate tool for assessment of bowel disease and of various com-
plications of CD. The lack of non-ionizing radiation exposure is an important advantage of this
imaging modality. Familiarity with common and pathognomonic imaging features of CD is essential
for every clinician that is involved in inflammatory bowel disease (IBD) patients' care.
This review is aimed to describe the indications for performing MRE in CD, essentials of MRE
techniques and typical radiological findings in patients with CD to aid the IBD doctor in daily
practice.
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Crohn's disease (CD) is a chronic inflammatory disease of
the intestinal tract that frequently affects young patients.
Although CD may involve any part of the digestive tract, small
bowel involvement occurs in at least 70% of the patients.1 As
this section of the digestive tract is not easily accessible by
conventional endoscopic techniques and because the inflam-
matory process may penetrate beyond the bowel wall,
cross-sectional imaging is frequently employed in CD patients,
both for assessing small bowel disease severity and for
detection of extra-luminal complications.
Both computed tomography (CT) and MRI enable clear
visualization of the entire length of the intestinal tract
along with various extra-and intra-intestinal complications
such as abscesses, enterovisceral and perianal fistulae,
perforation and strictures. The diagnostic accuracy of MR
enterography (MRE) and CT enterography (CTE) is compa-
rable for diagnosis of CD and it's complications.2 Although
CT is still the more commonly employed diagnostic modality
in CD worldwide, MRE possesses several important advan-
tages that have lead to a steep increase in its utilization in
the recent years.3
MRE provides an improved superior soft tissue contrast
resolution in comparison to CT, enabling a superior visualiza-
tion of the inflammatory and fibrotic characteristics of the
bowel wall. Recently, diagnostic indices based on MRE-based
quantitative assessment of disease severity have been devel-
oped. MRIA (magnetic resonance index of activity) is com-
prised of a formula incorporating wall thickness, edema,
ulceration and relative contrast enhancement of the bowel
calculated for each bowel segment.4 This index demonstrated
a significant correlation (r=0.82, p=0.001) with the endo-
scopic severity index CDEIS (Crohn's disease endoscopic index
of severity) with a high accuracy for the detection of disease
activity (area under the receiver operating characteristic
(ROC) curve 0.891, sensitivity of 81%, specificity of 89%) and
for the detection of ulcerative lesions (area under the ROC
curve 0.978, sensitivity of 95%,specificity of 91%) in the colon
and terminal ileum,4,3 Another potentially valuable prognostic
tool based on MRE is the Lemann score, aimed at the
evaluation of cumulative destructive damage to cause by CD
to different segments of the bowel.5 For each CD location,
independent variables including presence of a segment with
at least grade 1 (wall thickening b3 mm and/or segmentalenhancement without prestenotic dilatation), 2 (wall thick-
ening ≥3 mm and/or mural stratification without prestenotic
dilatation), or 3 (stricture with prestenotic dilatation lesion)
or surgery; number of segments with at least grade 1, 2, or 3
lesion/surgery; the proportion of segments containing grade
1, 2, or 3 lesion/surgery will also be assessed (if feasible) in the
case of small bowel location. The scores of different com-
partments are integrated into the index.5 Monitoring of
response to anti-inflammatory therapy may become another
potential indication for MRE, enabling accurate and non-
invasive method of surveillance.6
Pelvic MRI is a cornerstone modality in the evaluation of
perianal CD due to its capability for providing detailed and
high-quality images of the sphincter complex that are es-
sential for evaluation of pelvic disease. Response to therapy in
perianal CD can also be monitored by pelvic MRI.7,8
The impact of cumulative radiation exposure associated
with recurrent CT examinations is another factor to be borne
in mind when choosing between different imaging modalities.
CD patients, who often develop symptoms at puberty and in
young adulthood, and tend to develop complications requiring
urgent interventions, are particularly subject to this kind of
radiation exposure. It has been reported that up to 10% of CD
patients have been exposed to a potentially harmful levels
of radiation exposure defined as ≥50 milli-sieverts (mSv)
(equivalent to 5 CT abdomen examinations).9 Radiation ex-
posure associated with CT imaging may vary significantly. Use
of multidetector CT may allow a reduction of 10–60% in the
radiation exposure attributed to efficient detector configura-
tion, automatic exposure controls, improved filters, and
image post-processing algorithms.10 CT enteroclysis facilitat-
ed by luminal distention with a contrast agent delivered by a
nasoenteric tube allows for a further reduction of the
radiation exposure.11 Recently, low-dose radiation techniques
are based on modifications of exposure time, alterations
of voltage and amperage and noise-reduction filters.12 An
alternative low-dose technique using concentrated oral con-
trast (Telebrix 9% instead of the commonly used 3% con-
centration), no intravenous contrast and a high noise index
(MBCT – modified small bowel CT) valuable for depicting
strictures and obstruction, along with some features compat-
ible with inflammation, such as mesenteric fat hypertrophy
and prominent vasa recta, was described.13 Although resulting
in lower quality images, these techniques are capable of
obtaining accurate and diagnostic images.14,15
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persist even with lower accumulative doses of radiation.16
Hence, imaging technique that is not associated with ionizing
radiation, such as MRE, is particularly attractive in a cohort of
young patients subject to repeated imaging.
2. Magnetic resonance technique for
evaluation of small bowel
MRE allows multiplanar imaging of the intestinal tract.
Obtaining a diagnostic MRE examination requires adequate
distention of the bowel lumen achieved by means of ingestion
of oral contrast, reduction of peristalsis by spasmolytics and
injection of intravenous contrast material (gadolinium).
Image acquisition is obtained with several sequences. MR
enterography imaging protocols vary significantly due to
differences in equipment and personal expertise.17 A more
detailed technical description of the MRE sequences is beyond
the scope of this review and could be found elsewhere.18 In
addition, a specific sequence can be labeled under different
names for different MRImachines, as themanufacturers do not
necessarily employ a homogenous terminology for descrip-
tion of the sequences. However, certain basic elements are
common to most CD imaging protocols for CD. Fast sequences
capable of acquiring T1-w and T2-w images in a single
breathold are crucial for obtaining diagnostic images and
reduction of artifacts.19 In our practice, we use a 1.5 Tmagnet
Signa HDX, General Electric Medical Systems (Wisconsin,
Milwaukee, USA), equipped with a phased-array 8-element
coil with the following sequences
• FIESTA-steady state free precession (SSFP) sequence in
axial, coronal and sagittal planes;
• FSE (fast spin echo) T2-w sequence with fat suppression,
in axial and coronal planes;
• T1-w 2D FSPGR (fast spoiled gradient echo) with fat
suppression and breath hold in axial and coronal planes.
T1-w 3D LAVA is performed pre- and 60 s post-intravenous
contrast administration with fat suppression and breath hold
in axial planes. The same sequence, in the coronal plane, is
acquired 120 s after the administration of the intravenous
contrast medium.
In T2-w sequence, the positive or biphasic oral contrast
agent appears brighter (hyperintense) compared to the darker
(hypointense) thickened bowel wall (Fig. 1A), allowing visual-
ization of luminal stenosis and mural thickening. In T1-w
sequence ingested contrast agent appears hypointense com-
pared to the bowel wall, and following gadolinium injection,
the inflamed wall enhances and appears hyperintense com-
pared to the hypointense luminal content indicating active
inflammation20,21 (Fig. 1B and C).
Cine steady-state free precession (SSFP) (referred to as
FIESTA, bFFE,true FISP by different manufacturers) is an ultra
rapid multiplanar sequence that enables high spatial resolu-
tion images especially sensitive for detection of tubular
structures such as sinus tracts and fistulae22 (Fig. 1D).
Dynamic contrast enhanced (DCE) MRI is a method of
investigating vascular structure and function by tracking the
pharmacokinetics of injected low-molecular weight contrast
agents before, during and after the injection of contrast. Itis sensitive to alterations in vascular permeability, extracel-
lular, extravascular and vascular volumes and blood flow.
Quantitative analysis of dynamic MRI images was evalu-
ated in small studies for assessment of bowel inflammation
and disease chronicity with inconsistent results.23–25
In addition, we use a multiphase multisection coronal
SSFP sequence that covers the entire small bowel and colon
in order to follow peristaltic contraction of the bowel. These
images may then be displayed as a cine loop to assess bowel
motility, stenosis and dilatation. Because of the high image
contrast, this type of sequence is also helpful for assessing
mesenteric vascularity and lymphadenopathy.
Fat suppression is a sequence depressing the bright signal
intensity (white) of the fat allowing for improving visualization
of uptake of contrast material and detection of inflamma-
tion.26 It is especially important when contrast material is
contraindicated (renal insufficiency, pregnancy).
The acquisition time for an appropriate and diagnostic MRE
examination may vary from 16 min to 1 h, usually approxi-
mating 20–30 min, depending on the protocols employed.19,27
Three main types of oral contrast agents exist – negative
(hypointense on both T1-w and T2-w sequences), positive
(hyperintense on both sequences) and the most commonly
used biphasic (polyethylene glycol, sorbitol, lactulose etc.),
that appear hyperintense on T2-w and hypointense on
T1-w28 images. The contrast agent can be delivered orally
or facilitated by a nasojejunal tube (MR enteroclysis). The
oral contrast is delivered in large quantities (up to 2 l),
usually through an automated pump. Several studies have
compared the diagnostic efficacy of oral contrast MRE and
MR enteroclysis. In a prospective study of 40 patients with
CD, MR enterography compared with MR with oral contrast
was statistically better when visualizing superficial abnor-
malities (pb0.01), and no statistically significant differences
were found in assessing the diagnostic efficacy between
MR examinations for the depiction of mural stenosis and
fistulae.29 In a prospective study of 48 patients, even though
enteroclysis was able to achieve a better distention of the
small bowel, the diagnostic accuracy of both techniques was
similar.30 Importantly, enteroclysis is associated with a
significant discomfort for the patient and is usually achieved
by fluoroscopy that is associated with ionizing radiation.
When using oral contrast, a total volume of 1.5 l is usually
ingested, and image acquisition should be performed 40–
60 min after the ingestion in order to achieve maximal bowel
distention.27
Elimination of bowel peristalsis is mandatory to improve
image quality, and is achieved by the use of spasmolytics such
as glucagon or scopolamine. Reduction of peristalsis is most
important for fast gradient-echo sequences performed after
the administration of intravenous contrast material and also
may help reduce intraluminal flow artifacts (as can be noticed
on Fig. 9). In our practice, we administer intravenous glucagon
(1 mg) In a 50 ml saline infusion 10 min before the patient is
placed on the table, with continued slow drip during the
examination to prevent adverse reaction such as nausea and
vomiting.
Injection of intravenous gadolinium during the examina-
tion is necessary for detection of enhancement of inflamed
structures. In our institution, we administer 20–30 ml of
gadolinium corresponding to a dose of 10–15 mmol, at
a rate of 1 ml/s, followed by a flush of 30 ml of saline
A B
C D
Figure 1 “Star sign” representing convergent enteroenteric fistulae between inflamed ileal loops. T2-w (A) andT1-w (B) pre-gadolinium
injection (with fat suppression). (C) T1-w post-gadolinium injection (with fat suppression). (D) FIESTA.
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(Buscopan, 40 mg IV) can be employed.31
3. Typical manifestations of CD on MRE
3.1. Mural small bowel disease
MRE is very sensitive for recognizingmural small bowel disease.
Most common signs of small bowel involvement include bowel
wall thickening, mucosal irregularity and mural attenuation.
Inflamed bowel wall appears hyperintense on T2- w sequences
and enhances after gadolinium injection on T1-w sequences
(Fig. 2). However, fibrostenotic lesions may also be associated
with a high contrast uptake resulting from increased perme-
ability of the local vasculature.25 In this case, T2-w fat
saturated images may be instrumental in diagnosing active
inflammation by demonstration a presence of an edema in
active. In the study by Grieser et al.,32 ROC (receiver
operating curve) analysis of the total inflammatory score
demonstrated an AUC (area under the curve) of 0.93
(pb0.001) for T2-activity.In a study by Rimola et al., a significant correlation with
disease activity as represented by CD endoscopic index of
severity (CDEIS) was demonstrated for segment wall thick-
ness (p=0.007), relative contrast enhancement (calculated
using a formula incorporating wall signal intensity before
and after gadolinium injection) (p=0.01), presence of
edema (p=0.02) and ulcers (p=0.003) on MRE.4
However, correlation of clinical and MRE staging of CD is
associated with certain areas of uncertainty. A systematic
review by Horsthuis et al. has demonstrated that MRE was
accurate for grading frank disease 91% of the cases, but in only
62% of the patients withmild disease or remission, overstaging
patients in remission in 38% of the cases. These discrepancies
could be explained by the lack of gold standard stemming
from inherently different nature of the diagnostic methods
employed (ileocolonoscopy being capable of visualizing only
the luminal surface as opposed to MRE's ability to evaluate
all the layers of the bowel wall along with extraluminal
pathology), in addition to a lack of defined cutoff points for
differentiation of different stages of the disease, and the
subjective selection of the bowel segments for disease activity
A B
Figure 2 Terminal ileitis: inflamed mucosa. T1-w (A) pre- and (B) post- gadolinium injection with enhancement of terminal ileum
(arrow).
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mostly patients with frank active disease rather than patients
with mild or inactive disease.33
Additional signs of mural disease may include ulcerations,
“cobble stone” appearance characteristic of multiple con-
tinuous bowel wall ulcerations (Fig. 3) and stratification of
the bowel wall (heterogeneous enhancement of the layers ofA B
Figure 3 Mural thickening with mucosal irregularity, ulcers and e
demonstrating irregular enhancement of the mucosa mimicking “co
fistula (arrow). (B) FIESTA: Mural thickening due to inflammation cathe abdominal wall with hyperintense appearance of the
mucosa and the serosa, and hypointense appearance of the
muscularis layer on T1-w sequence) (Fig. 4), the latter
reported to be associated with histologically proven acute
bowel wall inflammation in several studies. However, this
enhancement pattern was demonstrated to be also associ-
ated with fibrostenotic lesion.34nhancement. (A) Coronal view T1-w post-gadolinium injection
bble stone appearance” with deep ulceration and enteroenteric
using luminal narrowing (arrowhead).
A B
Figure 4 Distal ileum: mural thickening and layering. T2-w (A) and T1-w post-gadolinium injection (B): mural thickening (arrowhead)
and stratification (arrow). Notice mucosal enhancement (bright), submucosal edema (darker) and muscularis propria enhancement
(bright).
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Substantial mural disease may be associated with extra-mural
involvement that is characterized by several pathognomonic
signs.
Mesenteric vascular engorgement (“comb sign,” Fig. 5),
usually resulting from increased inflammatory activity, can be
seen as high-signal intensity parallel lines oriented perpen-
dicular to the longitudinal access of the affected bowel wall on
T1-w contrast-enhanced images,27 frequently adjacent to a
bowel segment showing signs of active disease. On FIESTA
(fast imaging employing steady state acquisition) and T2-w
sequences the comb sign can be seen as black line on thewhite
mesenteric fat background (Fig. 10A).
Fat wrapping (“creeping fat,” Fig. 6) can be described as
a mass effect caused by proliferation of mesenteric resulting
in a displacement of intra-abdominal viscerae or vascular
structures. Fat wrapping is usually asymmetric and tends to
appear more frequently on the mesenteric side of the bowel
wall.27 The hypertrophic fat is best seen on steady state
acquisition (FIESTA sequences), as also seen in Fig. 1A and D.
Mesenteric lymphadenopathy presenting as enlargement,
hyperenhancement and edema of the lymph nodes on the
T1-w sequences post-gadolinium injection, as seen in Fig. 7,
is highly pathognomonic for active CD.18,35 Nodal edemaA
Figure 5 Comb sign representing congested mesenteric vessel ad
suppression. Notice mural thickening and enhancement post-gadolinresulting from inflammation is better demonstrated on fat-
suppressed images. Alternatively, non-enhancing lymphade-
nopathy may imply a different etiology such as malignancy or
chronic infection such as tuberculosis or hystoplasmosis.27
3.3. Mural colonic disease
Inflammation of the colonic wall can also be clearly demon-
strated on MRE. The signs of colonic mural disease such as
bowel thickening, mucosal ulcerations and mural enhance-
ment are analogous to those of small bowel disease. Long-
standing severe mucosal inflammation of the colonic mucosa
may appear as polypoid structures (Fig. 8).
3.4. Stenotic disease
The accuracy of MRE for detection of stenosis in CD has been
well established, with a pooled sensitivity and specificity of
88% and 95%, respectively.36–38 Bowel stenosis usually appears
as a thickened and enhanced segment adjacent proceeded by
a markedly distended segment (“prestenotic dilatation”).
Establishing the nature of stenosis (whether predominantly
active inflammatory vs. fibrostenotic) is of great therapeutic
interest, an inflammatory stricture may potentially respond toB
jacent to the diseased jejunal loop (arrowhead). T1-w with fat
ium injection.
AB
Figure 6 Mesenteric hypertrophy (creeping fat) (arrow). (A) FIESTA coronal view. (B) FIESTA axial view. Notice cholelithiasis
(arrowhead).
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will probably require surgical or endoscopic intervention
(Fig. 9). The ability of MRE to obtain high spatial resolution
with visualization of distinct enhancement patterns may be
useful for guiding therapy in stenotic CD. In a study by Fornasa
et al.,39 evaluation of inflammatory activity as defined by
T2-w signal intensity and post-gadolinium T1-w enhance-
ment in patients with small bowel stricture has allowed
reliable differentiation between active inflammatory and
fibrostenotic strictures, with 96% of patients diagnosed with
active inflammatory stricture achieving short-term responseFigure 7 Enlarged mesenteric lymph nodes (arrow). T1-w post-
gadolinium injection. Thick enhancing ileal wall (arrowhead) and
enhancing mesenteric hypertrophy with congested mesenteric
vessels (star).to anti-inflammatory therapy. De Vescovo et al. demonstrated
an association of layered enhancement (mucosa and serosa)
of the bowel wall with active histological inflammation, as
opposed to homogenous enhancement characteristic of
fibrosis (Fig. 4).3.5. Penetrating disease
MRE allows accurate diagnosis of penetrating complications of
CD. Current ECCO40 guidelines recommend either CT or MRE
for diagnosis of intra-abdominal complications of CD, with a
pooled sensitivity of 76% and specificity of 96%2,37,41–43
comparable to the accuracy of CT.3.6. Fistulae
Different types of intra-abdominal fistulae can be detected in
CD patients by MRE. An enteroenteric fistula may appear as an
enhanced sinus tract between adjacent bowel loops (Fig. 3). A
“star sign” (Fig. 1) represent a conglomerate of inflamed
bowel loops interconnected by multiple fistulous tracts (fig).
Detection of enterovesical (Fig. 9) and enterovaginal (Fig. 10)
fistulae is challenging, and may be facilitated by appearance
of an air bubble in the urinary bladder or vagina that are
usually air-free, commonly in a proximity to a diseased bowel
loop (Fig. 11).3.7. Abscesses
Abscesses appear as fluid collections encapsulated by an
enhanced wall discontinuous with bowel lumen, which may
also contain air (Fig. 12). Several studies have evaluated the
accuracy of MRE for diagnosis of intra-abdominal abscesses
in CD, with pooled sensitivity of 86% and specificity of 93%
which is similar to the reported pooled accuracy of
CT.2,37,42,43 MRI may facilitate percutaneous guided drainage
of the abscess and is useful for post-drainage follow-up.
Figure 8 Descending colitis with mural thickening. (A) T1-w post-gadolinium injection. (B) FIESTA. Notice mural thickening (arrows)
and pseudopolyps (arrowheads).
610 M.M. Amitai et al.3.8. Thrombotic complications
Inflammatory bowel diseases are associated with an increased
risk of thromboembolic complications, such as deep venous
thrombosis, pulmonary embolism and portal or mesenteric
vein thrombosis.44,45 Long-standing mesenteric vein throm-
bosis may appear as a cutoff of the mesenteric vein (rat-tail
sign). Liver infarcts may accompany mesenteric vein throm-
bosis caused by pylephlebitis. Mesenteric/portal vein throm-
bosis may result in portal hypertension accompanied by
ascites and varices (Fig. 13).
3.9. MRE in pregnant women with CD
MRE is invaluable when cross-sectional imaging is indicated
in a pregnant patient (Fig. 14), as CT is associated with
ionizing radiation potentially harmful for the fetus.A
Figure 9 Bowel obstruction. (A) Coronal T1-w post-gadolinium i
(arrow). (B) Coronal FIESTA: fibrostenotic stricture causing marked
increase peristaltic proximal to stenosis.Although there are limited data suggesting fetal safety of
magnetic resonance examinations, this modality is usually
avoided in the first trimester. Intravenous gadolinium com-
pounds cross the placenta and may be demonstrated in the
fetal circulation and should be used judiciously.46
3.10. Postsurgical complications and recurrence
Abdominal surgery could be associated with a multitude of
intra-abdominal complications such as anastomotic leaks,
abscesses (Fig. 12), stoma-associated complications (Fig. 15)
and bowel obstruction. MRE, although not always readily
available in these frequently urgent settings, still comprises
a possible alternative to CT imaging for these patients. MRE
could be also instrumental in monitoring post-operative
disease recurrence, with a good correlation of an MR-based-
score with an endoscopic Rutgeerts score.47B
njection: enhancing inflammatory stricture in the distal ileum
distention of ileal loops. Notice the artifact on (A) secondary to
AB
Figure 10 Enterovesical fistula appearing as mural thickening with air in the urinary bladder. (A) FIESTA. (B) T1-w post-gadolinium
injection. (A) Coronal view: distal ileitis with mural thickening (arrow) adjacent to the urinary bladder. Notice comb sign (arrowhead).
(B) Axial view: bubble of air in the urinary bladder (arrowhead) consistent with pneumaturia secondary to the enterovesical fistula.
A
B
Figure 12 Abscesses (arrows). (A) FIESTA: coronal view, abscess following resection of appendix involved by Crohn's disease in a
pregnant patient. (B) Axial view T1-w post-gadolinium injection: abdominal wall abscess. Notice enhancement of abscess capsule and
necrotic nonenhancing fluid (pus) and adjacent inflamed ileal loop in the pelvis (arrowhead).
A B
Figure 11 Rectovaginal fistula secondary to proctitis with mural thickening. T1-w post-gadolinium injection. (A) Sagittal view of
thickened rectum (arrow) with perirectal fat hypertrophy (star). Notice air bubble between the rectum and the vagina (arrowhead).
(B) Axial view demonstrating air in the vagina (arrowhead) and the fistula tract from the rectum (arrow).
611MRE in Crohn's disease: A guide to common imaging manifestations for the IBD physician
A B
Figure 13 Mesenteric vein thrombosis (two different patients). (A) Coronal FIESTA. (B) Coronal T1-w post-injection. (A) Thrombus
in mesenteric vein (arrow.) (B) Mesenteric varices (thin arrows). Notice enhancing star sign (arrowhead).
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MRI is a cornerstone modality in evaluation of pelvic and
perianal CD (Figs. 16 and 17). When compared with surgical
examination under anesthesia, the sensitivity and specificity
of MRI for detecting fistula tracks were 100% and 86%; for
abscesses, 96% and 97; for horseshoe fistulas, 100% and 100;
and for internal openings, 96% and 90%, respectively.48 In
the study be Beets-Tan et al.,48 additional information
leading to modification of the surgical procedure was
obtained in 40% of the patients with perianal CD who were
previously evaluated by endoanal ultrasound. A combination
of these two modalities may further increase the diagnostic
accuracy.49 Pelvic MRI may also play an important role in
monitoring anti-TNF therapy in perianal CD.50–52A
Figure 14 Crohn's colitis in a pregnant patient. (A) Axial FIESTA.
(7 mm) and comb sign (arrow). (B) Upward displaced thickened wall o4. Limitations of MRE studies
Several important limitations of MRE in comparison to CT
imaging should be acknowledged. CT provides superior
overall image quality with better spatial resolution, requir-
ing a significantly shorter acquisition tome (8–10 s for CTE
and 20–30 min for MRE).20 MRI is not suitable for claustro-
phobic patients, although recently utilization of open MRI
machines for these patients has been reported.53–55 In many
countries, MRI scanners are currently less accessible and
significantly more costly,20,28,56 especially in the smaller
and more peripheral centers.
Despite these limitations, MRE possesses a diagnostic
accuracy similar to CTE sparing the exposure to non-ionizing
radiation, and thus should be preferred when possible,B
(B) Coronal FIESTA. (A) Descending colitis with mural thickening
f sigmoid colon with comb sign (arrow).
A B C
Figure 15 Postoperative complication: inflammatory stenosis of ileostomy. Coronal FIESTA (A) and T1-w (B) post-gadolinium
injection. (C) Distended neoterminal ileum due to recurrence of the disease at the ileostomy site, with thickening and enhancement
of the stoma after gadolinium injection (arrows).
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perianal CD, MRI is the diagnostic modality of choice due to
its superior soft tissue visualization enabling accurate
diagnosis and staging of perianal fistulae.48,49
5. Summary
MRE is an imaging modality that is growing in usage and
importance in CD diagnosis and follow-up. Clinicians caring for
these patients should be familiar with MRE techniques, as
well as with the limitations and strengths of this modality
as outlined in the present review. Moreover, because this
modality is likely to become even more prevalent as a
diagnostic imaging tool for evaluating CD patients in the near
future, clinicians may find it increasingly useful to acquaintA B
C
Figure 16 Complex perianal and pelvic fistula. T1-w post-gadolinium
abscess (arrow). (B) Axial view demonstrating same abcess located beh
(thin arrow). (C) Axial view demonstrating two fistulous tracts: one f
tract pointed antero-superiorly (thin arrow).themselves with the appearance of the different radiological
features of the disease on MRE, as provided in this practi-
cal guide. Improved familiarity and understanding of the
strengths and limitations of this imaging modality by the
clinician will facilitate better inter-disciplinary co-operation
with the radiologist for both in the choice of the imaging
modality and in the interpretation of the results obtained and
will hopefully lead to improved patient's care and outcome.Conflicts of interest
Dr. Ben-Horin has received lecturer fees from Abbott and
Schering Plough. Prof. Eliakim has received lecturer fees from
Abbott. Other authors have no conflicts of interest to declare.injection. (A) Coronal view of the perianal fistula forming a pelvic
ind the uterus (arrowhead). Notice an additional presacral abcess
rom the anal canal to the right gluteus (arrowhead), and another
IA
B
Figure 17 Ischiorectal abcess. Axial T2-w (A) and coronal T1-w post-gadolinium injection (B). Abscess in the left ischiorectal fossa
(arrow).
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